Aldo-keto reductase 1B10 promotes development of cisplatin resistance in gastrointestinal cancer cells through down-regulating peroxisome proliferator-activated receptor-γ-dependent mechanism
Graphical abstract
Introduction
Cisplatin (cis-diamminedichloroplatinum, CDDP), a first member of platinum-based chemotherapy drugs, is widely used to treat various types of cancer, such as malignant lymphomas and lung, gastrointestinal, esophageal, ovarian, bladder, prostate and cervical cancers. The platinum drug interferes with growth of the cancer cells through intra- and inter-strand crosslinking of the DNA helix and the resulting inhibition of replication and synthesis of nucleic acids, hereby leading to the cancer cell death [1], [2]. Besides inhibiting the cancer cell proliferation, CDDP is considered to damage the cancer cells by the enhanced formation of reactive oxygen species (ROS), which trigger apoptosis towards cancer cells through DNA injury, mitochondrial dysfunction, activation of p53- and caspase-signaling cascades, and cell cycle arrest [2], [3], [4]. Despite the potent anticancer action of CDDP, the continuous exposure easily gives rise to hyposensitivity to the drug, so-called chemoresistance, as well as onset and development of severe side-effects including nephrotoxicity [4]. Induction of chemoresistance in cancer cells limits efficacy of the anticancer drug and consequently imposes complexed multidrug therapy on the cancer patients. In many cases, it also forms the incurable malignant cancer cells featuring overgrowth and elevation of invasive and metastatic capacities. Therefore, it is hoped that novel medicine to inhibit function and/or expression of molecules requisite for the gain of CDDP resistance is developed. Mechanisms of chemoresistance including cellular uptake and efflux of CDDP and potentiation of the DNA-repair and cytoprotective capacity have been suggested so far [2], [5], [6]. In addition, caudal type homeobox 2 [7], autophagy-related gene-5 [8] and syndecan-1 [9] have been more recently proposed as the target molecules for developing the drug resistance.
Members of the aldo-keto reductase (AKR) superfamily are NAD(P)(H)-dependent oxidoreductases that metabolize carbohydrates, steroids, and prostaglandins, as well as exogenous carbonyl compounds such as drugs and toxicants [10]. Among human 15 members of this superfamily, AKR1C1, AKR1C2 and AKR1C3 have been shown to be highly expressed and associated with resistance against anticancer drugs such as anthracyclines, CDDP and methotrexate [11], [12], [13]. The three AKR1C isoforms are hydroxysteroid dehydrogenases with broad substrate specificity for carbonyl compounds including 4-hydroxy-2-nonenal (HNE), a major product of lipid peroxidation through oxidative stress, but it remains unclear as to how the enzymes confer the drug resistance. In addition, AKR1B10, i.e. human aldose reductase-like protein, is up-regulated in many types of solid tumors [14], [15], [16], [17], [18], and its gene silencing inhibits replication of colorectal cancer cells [19] and tumor growth in vivo [18]. Although detailed mechanisms of the AKR1B10-initiated tumorigenic action are still unclear, it is inferred to be due to metabolizing retinoids [20] and isoprenoids [21], regulating fatty acid synthesis [22], and detoxifying cytotoxic aldehydes such as acrolein [19] and HNE [23]. Thus, AKR1B10 has been recognized as a potential molecular target for preventing cancer proliferation as well as a diagnostic tumor marker. Besides, AKR1B10 was found to be overexpressed in medulloblastoma cell lines resistant to cyclophosphamide [24]. We also showed that mitomycin C (MMC) [25] or doxorubicin (DOX) resistance in gastrointestinal cancer [26] as well as CDDP resistance in lung cancer cells [27] are mediated by up-regulation of AKR1B10, suggesting a close association of the enzyme up-regulation with cancer chemoresistance.
Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors that belong to the nuclear receptor superfamily [28]. PPARs regulate transcription of target genes by binding to their peroxisome proliferator-response elements as heterodimers with retinoid X receptor. The PPAR receptor family is comprised of the three subtypes, PPARα, PPARβ/δ, and PPARγ, each of which mediates important physiological actions in metabolism of lipids and sugars. In addition to the energy homeostasis, ligands for PPARs are considered to act as key regulators for proliferation of gastrointestinal cancer cells. For example, treatment with ligands of PPARα and PPARγ inhibits proliferation of the cancer cells [29], [30]. Especially, PPARγ is closely linked to growth suppression and death of cancer cells, and incubation with the ligands appears to potently induce apoptosis in many kinds of cancer cells such as breast, thyroid, bladder, esophageal, gastric, colon, lung, and prostate cancers and lymphomas [31]. In addition, PPARγ is also associated with CDDP resistance of ovarian cancer [32], [33], bladder cancer [34] and malignant glioma [35], and that treatment with its ligands sensitizes the cancer cells to the drug. Furthermore, AKR1C3 is reported to facilitate proliferation of cancer cells such as myeloid leukemia cell and skin squamous cell carcinoma via metabolizing prostaglandin D2 into prostaglandin F2α, not 15-deoxy-Δ12,14-prostaglandin J2, an endogenous PPARγ agonist [36], [37], [38], [39], [40]. However, it is uncertain whether the PPARγ-dependent mechanism is involved in acquisition of CDDP resistance and expression of other AKRs, except for AKR1C3, in gastrointestinal cancer cells.
In this study, we have generated CDDP-resistant variants of gastrointestinal cancer (MKN45 and LoVo) cells, monitored alterations in factors involved in antioxidant response of the cells with development of CDDP resistance, and found a significant up-regulation of AKR1B10 as a pivotal process for promoting the chemoresistance. We have also investigated an association of PPARγ with the CDDP resistance, and finally evaluated efficacy of combined treatment with AKR1B10 inhibitor and PPARγ ligand for overcoming resistance in the resistant cells.
Section snippets
Materials
CDDP was purchased from Wako Pure Chemical Industries (Osaka, Japan). TRIzol reagent, Superscript III reverse transcriptase, oligo (dT)12-18 primer and Lipofectamine 2000 were obtained from Invitrogen (Carlsbad, CA); rosiglitazone, N-acetyl Asp-Glu-Val-Asp-7-amido-4-methylcoumarin (AMC), N-succinyl-Leu-Leu-Val-Tyr-AMC and N-acetyl-l-cysteine (NAC) were from Sigma-Aldrich (St. Louis, MO); (S)-(+)-1,2,3,4-tetrahydro-1-naphthol (S-tetralol) and oleanolic acid (OA) were from Tokyo Chemical Industry
Facilitation of antioxidant properties with CDDP resistance
Treatment of MKN45 cells for 24 h with CDDP provoked the viability loss, which was remarkable at its concentrations of more than 50 μM (Fig. 1A). In addition, the high concentrations of CDDP activated caspase-3, a downstream target for the ROS-dependent apoptotic signaling cascade [48] (Fig. 1B). Moreover, concomitant treatment with an antioxidant NAC significantly reduced the cellular damage by CDDP, although the inhibitory effect of the antioxidant is incomplete. The results clearly indicate
Discussion
In the present study, we showed that resistance development of gastrointestinal cancer cells against CDDP elevates the antioxidant capacity through increases in glutathione content, AKR expressions and 26S proteasome-based proteolytic activity. Since up-regulation of AKR1B10 was the most remarkable event among the alterations in the antioxidant factors (Fig. 2, Fig. 3), we highlight the importance of AKR1B10 as a crucial factor for acquiring CDDP resistance of gastrointestinal cancer cells.
Conflict of interest
All authors declare that there are no conflicts of interest concerning this work.
Acknowledgement
This work is supported in part by a Grant-in-Aid for Scientific Research (C) (25460068 and 15K10601) from the Japan Society for the Promotion of Science.
References (63)
- et al.
Cisplatin in cancer therapy: molecular mechanisms of action
Eur. J. Pharmacol.
(2014) - et al.
Role of oxidative and nitrosative stress in cisplatin-induced nephrotoxicity
Exp. Toxicol. Pathol.
(2009) - et al.
The role of DNA repair pathways in cisplatin resistant lung cancer
Cancer Treat. Rev.
(2014) - et al.
Transcriptional regulation of aldo-keto reductase 1C1 in HT29 human colon cancer cells resistant to methotrexate: role in the cell cycle and apoptosis
Biochem. Pharmacol.
(2008) - et al.
Roles of rat and human aldo-keto reductases in metabolism of farnesol and geranylgeraniol
Chem. Biol. Interact.
(2011) - et al.
Aldo-keto reductase family 1 member B10 promotes cell survival by regulating lipid synthesis and eliminating carbonyls
J. Biol. Chem.
(2009) - et al.
Role of human aldo-keto-reductase AKR1B10 in the protection against toxic aldehydes
Chem. Biol. Interact.
(2009) - et al.
Acquisition of doxorubicin resistance facilitates migrating and invasive potentials of gastric cancer MKN45 cells through up-regulating aldo-keto reductase 1B10
Chem. Biol. Interact.
(2015) - et al.
4-Hydroxynonenal and PPARγ ligands affect proliferation, differentiation, and apoptosis in colon cancer cells
Free Radic. Biol. Med.
(2007) - et al.
Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy
Cancer Cell
(2014)
Knockdown of AKR1C3 exposes a potential epigenetic susceptibility in prostate cancer cells
J. Steroid Biochem. Mol. Biol.
Decreased levels of AKR1B1 and AKR1B10 in cancerous endometrium compared to adjacent non-cancerous tissue
Chem. Biol. Interact.
15-Deoxy-Δ12,14-prostaglandin J2 regulates mesangial cell proliferation and death
Kidney Int.
Design, synthesis and evaluation of caffeic acid phenethyl ester-based inhibitors targeting a selectivity pocket in the active site of human aldo-keto reductase 1B10
Eur. J. Med. Chem.
Kinetic studies of AKR1B10, human aldose reductase-like protein: endogenous substrates and inhibition by steroids
Arch. Biochem. Biophys.
Nitric oxide mitigates apoptosis in human endothelial cells induced by 9,10-phenanthrenequinone: role of proteasomal function
Toxicology
Determination of glutathione and glutathione disulfide in biological samples
Methods Enzymol.
Ceramide-induced intracellular oxidant formation, iron signaling, and apoptosis in endothelial cells: protective role of endogenous nitric oxide
J. Biol. Chem.
Pathophysiological roles of aldo-keto reductases (AKR1C1 and AKR1C3) in development of cisplatin resistance in human colon cancers
Chem. Biol. Interact.
Protective role of glutathione synthesis in response to oxidized low density lipoprotein in human vascular endothelial cells
Free Radic. Biol. Med.
Impaired expression of glutathione synthetic enzyme genes in mice with targeted deletion of the Nrf2 basic-leucine zipper protein
Biochim. Biophys. Acta
Nrf2-dependent induction of proteasome and Pa28αβ regulator are required for adaptation to oxidative stress
J. Biol. Chem.
Nrf2, a Cap’n’Collar transcription factor, regulates induction of the heme oxygenase-1 gene
J. Biol. Chem.
All-trans retinoic acid potentiates the chemotherapeutic effect of cisplatin by inducing differentiation of tumor initiating cells in liver cancer
J. Hepatol.
Low-dose all-trans retinoic acid enhances cytotoxicity of cisplatin and 5-fluorouracil on CD44(+) cancer stem cells
Biomed. Pharmacother.
Overexpression and oncogenic function of aldo-keto reductase family 1B10 (AKR1B10) in pancreatic carcinoma
Mod. Pathol.
Platinum-intercalator conjugates: from DNA-targeted cisplatin derivatives to adenine binding complexes as potential modulators of gene regulation
Curr. Top. Med. Chem.
Molecular basis of cellular response to cisplatin chemotherapy in non-small cell lung cancer
Oncol. Rep.
Platinum transporters and drug resistance
Arch. Pharm. Res.
Overexpression of CDX2 in gastric cancer cells promotes the development of multidrug resistance
Am. J. Cancer Res.
Upregulation of autophagy-related gene-5 (ATG-5) is associated with chemoresistance in human gastric cancer
PLoS One
Cited by (28)
Aldose reductase and cancer metabolism: The master regulator in the limelight
2023, Biochemical PharmacologyMoving toward a new horizon for the aldose reductase inhibitor epalrestat to treat drug-resistant cancer
2022, European Journal of PharmacologyCitation Excerpt :For example, it would be interesting to combine a proteasome inhibitor like bortezomib with EPA because bortezomib has been shown to dramatically increases mRNA levels of AKR1B10 (32-fold) and AKR1B1 (5-fold) in SW-480 colon cancer cells (Loeffler-Ragg et al., 2009; Ebert et al., 2011). Combinations of an AKR1B10 inhibitor with different platinum derivatives (cisplatin) or a taxane (docetaxel) could be proposed as well, to reduce drug resistance (Matsunaga et al., 2016; Endo et al., 2017). EPA is a well-known drug, used in human for decades for the treatment of diabetic peripheral neuropathy.
Caffeic acid and its derivatives as potential modulators of oncogenic molecular pathways: New hope in the fight against cancer
2021, Pharmacological ResearchCitation Excerpt :Doxorubicin (DOX) is another chemotherapeutic agent that can induce cell cycle arrest in cancer cells via inhibiting topoisomerase activity and preventing DNA and RNA transcription [28]. Increasing evidence have revealed the fact that proteasomal activity could be enhanced in DOX- and CP-resistant cancer cells [191–193]. In stomach and colon cancer cells, 26 S proteasome-based proteolytic activity enhances, especially chymotrypsin-like activity, mediating DOX and CP resistance.
Pathophysiological roles of autophagy and aldo-keto reductases in development of doxorubicin resistance in gastrointestinal cancer cells
2019, Chemico-Biological InteractionsCitation Excerpt :In addition, AKR1B10 and AKR1C3 have been recently proposed as potential targets for development of resistance towards some anticancer drugs such as DOX, mitomycin-C (MMC), cis-diamminedichloroplatinum (CDDP) and oxaliplatin (LOHP), because of aberrant expression of the enzymes in some kinds of anticancer drug-resistant cancer cells [9,14]. Indeed, our previous studies showed that AKR1B10 and/or AKR1C3 are associated with development of gastrointestinal cancer cell resistance to DOZ, MMC and CDDP, and suggested that the two enzymes function as regulators for the development of chemoresistance [13,15–17]. Autophagy is considered to play a wide variety of physiological and pathophysiological roles in development, differentiation, infection, and onset and progression of several diseases including cancer.
New insights into molecular mechanisms of rosiglitazone in monotherapy or combination therapy against cancers
2018, Chemico-Biological InteractionsCitation Excerpt :Cisplatin is one of the most effective chemotherapeutic drugs that are used for treatment of patients with colon cancer, but its continuous administration often evokes the development of chemoresistance. ROSI could increase the sensitivity to cisplatin in cisplatin resistant colon cancer LoVo cells [75]. Moreover, the combination of ROSI and non-traditional chemotherapy drugs could also have a synergistic anticancer activity.
The influence of peroxisome proliferator-activated receptor γ (PPARγ) ligands on cancer cell tumorigenicity
2018, GeneCitation Excerpt :On the other hand, Cisplatin resistant cancer cells reduce Cisplatin-induced oxidative stress through up-regulating of alde-keto reductase 1B10 (AKR1B10) and down-regulating of PPARγ, with an AKR1B10-dependent mechanism. Hence, it shows that combined treatment with AKR1B10 inhibitor and/or PPARγ agonist can be effective for eliminating Cisplatin-resistant cancer cells (Matsunaga et al., 2016). Anti-tumor effects of 6-iodolactone (6IL), an iodinated arachidonic acid derivative have been reported to mediate by PPARγ.